Reshaping the HIV treatment and prevention landscape
We have built an innovative pipeline:
62 potential vaccines and medicines
Phase I
C. difficile* vaccine
MenABCWY (2nd gen) vaccine
SAM (COVID-19 model) vaccine
SAM (rabies model) vaccine
BVL-GSK098* (ethionamide booster) TB
2556286* (Mtb inhibitor) TB
3186899* (CRK-12 inhibitor) visceral leishmaniasis²
3494245* (proteasome inh) visceral leishmaniasis
3882347* (FimH antagonist) uUTI
3923868 (P14kẞ inhibitor) viral COPD exacerbations
4182137* (VIR-7832) COVID-191
VIR-2482 (neutralizing monoclonal antibody) influenza
3739937 (maturation inhibitor) HIV
3326595* (PRMT5 inhibitor) cancer
3368715* (Type 1 PRMT inhibitor) cancer
3745417 (STING agonist) cancer
3901961* (NY-ESO-1/CD8a TCR T) cancer
3845097* (NY-ESO-1/TGFbR2 TCR T) cancer
4074386* (TSR-033, LAG3 antagonist) cancer
4362676* (Mat2A inhibitor) cancer
6097608 (CD96 antagonist)* cancer
Phase II
COVID-19 (SK Bioscience)*1 vaccine
Malaria (fractional dose)* vaccine
RSV paediatric vaccine
S. aureus*1 vaccine
Shigella* vaccine
Therapeutic HBV*1 vaccine
3036656* (leucyl t-RNA inhibitor) TB
3228836* (HBV ASO) HBV
3640254 (maturation inhibitor) HIV
3810109* (broadly neutralizing antibody) HIV4
bintrafusp alfa* (TGFß trap/anti-PDL1) BTC**
cobolimab* (TSR-022, TIM-3 antagonist) NSCLC
feladilimab* (3359609, ICOS agonist) solid tumours
linerixibat (IBATi) cholestatic pruritus in PBC
Phase III/Registration
Bexsero infants (US) vaccine
COVID-19 (Medicago)** vaccine
COVID-19 (Sanofi)** vaccine
MenABCWY vaccine 1st gen
Menveo liquid³ vaccine
MMR (US) vaccine
RSV maternal* vaccine
RSV older adults* vaccine
Rotarix liquid (US) vaccine
Shingrix immuno-compromised* vaccine
gepotidacin (2140944)* uUTI and GC
sotrovimab (VIR-7831)* COVID-19
cabotegravir LA HIV PrEP
**
Blenrep (anti-BCMA ADC)* multiple myeloma
Jemperli (PD-1 antagonist)* solid tumours*
letetresgene-autoleucel (3377794, NY-ESO-1 TCR)* SS³**
Zejula (PARP inhibitor)* ovarian & lung cancer
Benlysta + Rituxan SLE
depemokimab (LA anti-IL5 antagonist)* asthma
Nucala COPD / nasal polyps
otilimab (3196165, aGM-CSF inhibitor)* RA**
daprodustat (HIF-PHI) anaemia in CKD
Infectious Diseases
HIV (ViiV)
Oncology
Immunology/Respiratory
Opportunity Driven
COVID solutions
Note: Only the most advanced indications
are shown for each asset
EOS-448 (TIGIT antagonist)* cancer
2982772 (RIP1-k) psoriasis
3858279 (CCL17 inhibitor)* OA pain
3915393 (TG2 inhibitor)* celiac disease
2798745 (TRPV4 blocker)* DME
gsk
*In-license or other alliance relationship with third party; **Additional indications also under investigation; + GSK contributing pandemic adjuvant; 1. In Phase 1/2 study; 2. Transition activities underway to enable further progression by partner 3. In
potentially registrational Ph2 trial 4. Study start imminent (Jun/Jul21). EOS-448: subject to regulatory clearance of iTeos Therapeutics collaboration
RA: rheumatoid arthritis; OA: osteoarthritis; PBC: primary biliary cholangitis; NSCLC: non-small cell lung cancer; TB: tuberculosis; SLE: systemic lupus erythematosus; BTC: biliary tract cancer; uUTI: uncomplicated urinary tract infection; GC:
gonorrhoea; SS: synovial sarcoma ; DME: diabetic macular edema; PrEP: pre-exposure prophylaxis; CKD: chronic kidney disease
50View entire presentation